drugset / Trial / NCT04245709

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

NCT04245709

Phase 2 Completed 25 enrolled Dwight Koeberl, M.D., Ph.D.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of clenbuterol (taken by mouth) in subjects with ALS (amyotrophic lateral sclerosis) and to assess the effectiveness of clenbuterol with regard to motor function in subjects with ALS. Subjects will be in this study approximately 24 weeks. The study drug, clenbuterol, is taken twice a day. As part of this study subjects will have the following tests and procedures: medical history, vital signs, physical examination, blood tests, heart and lung function tests, muscle function test, ALSFRS-R (ALS Functional Rating Scale Revised), thyroid function and for women who can become pregnant, pregnancy tests.

Timeline

Start
2020-02-10
Primary completion
2021-03-10
Completion
2021-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clenbuterol Small molecule 80 ug Oral